Stock MEDCL MEDINCELL S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages MedinCell S.A.

Equities

MEDCL

FR0004065605

Market Closed - Euronext Paris
Other stock markets
 09:05:47 31/05/2024 pm IST 		5-day change 1st Jan Change
16.36 EUR -0.12% Intraday chart for MedinCell S.A. +9.50% +127.22%
15/05 Medincell: share price falls after disappointing clinical study CF
15/05 Transcript : MedinCell S.A. - Special Call

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Medincell: Update of the 2024 Financial Calendar
Medincell to Present at the 2024 Jefferies Global Healthcare Conference, June 4 to 6, 2024, New York
Medincell : recul du titre après une étude clinique décevante
Transcript : MedinCell S.A. - Special Call
Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial
Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial
Medincell to Host Videoconference on May 15, 2024, at 10:30 AM CEST to Discuss Company's Latest News, Outlook, and R&D Activities
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-749 as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
Medincell : le titre grimpe pour sa reprise de cotation
CAC40 : reste en vert dans un marché délaissé
Medincell : résultats positifs dans la schizophrénie
Medincell Listing Temporarily Suspended on Euronext Paris
Teva and Medincell's schizophrenia drug meets main goal of late-stage study
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
Teva Pharmaceuticals and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-?749 as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
CAC40 : en vert, poursuit sur sa lancée de la veille
MedinCell S A : Inside Information / Other news releases
Medincell : cotation suspendue dans l'attente d'un communiqué
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MEDCL Stock
  4. News MedinCell S.A.
  5. Other languages